Pivikto 150 MG Tablet is used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. It is prescribed in combination with fulvestrant for adults who have shown disease progression after an endocrine-based regimen. It belongs to the category of kinase inhibitors.
Before starting this medication, consult your doctor for the appropriate dosage and frequency based on your condition. It is essential to inform your healthcare provider about any existing medical conditions or medications you are taking. If you experience side effects, promptly notify your doctor. Continue the treatment for the prescribed duration to achieve the best results.